NIPTE is partner in newly announced National Biopharmaceutical Manufacturing Institute

The participating NIPTE team will primarily focus on biopharmaceutical formulations and product development, and FDA regulatory science.

The participating NIPTE team, currently comprises six member institutions (Universities of Connecticut, Kentucky, Kansas, Texas, Iowa, and Wisconsin), is a Tier 1 partner in NIIMBL. It will hold a seat on the Institute’s Governance Board and will play a major role in its initiatives primarily focusing on biopharmaceutical formulations and product development, and FDA regulatory science. The team will work in close collaboration with three other NIPTE member institutions, Purdue University, University of Maryland, and the University of Minnesota, which are Tier 1 partners alongside NIPTE.

“We are extremely pleased that advanced pharmaceutical manufacturing is now part of the Manufacturing USA network,” said Dr Vadim J. Gurvich, executive director of NIPTE and research associate professor at the University of Minnesota. “NIIMBL’s leadership has put together a very impressive partnership that will make a significant impact on biopharmaceutical manufacturing in this nation. As a key member, we will contribute to both research and education. For example, our Center of Excellence in Pharmaceutical Formulations will be a natural partner in NIIMBL.”